Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Cardiac Amyloidosis Market Expected To Reach $8.7 Billion By 2030 At 8.7% CAGR
The market for cardiac amyloidosis has experienced robust expansion in preceding years, demonstrating a significant upward trajectory. Projections indicate a progression from $5.73 billion in 2025 to an estimated $6.24 billion by 2026, reflecting a compound annual growth rate of 9.0%. This notable growth during the historical period can be attributed to several key factors, including heightened awareness of infrequently diagnosed cardiac conditions, sophisticated developments in diagnostic tools like echocardiography and MRI, a rise in documented instances of amyloidosis, the proliferation of specialized cardiology centers, and an increasing accessibility to supportive treatment modalities.
The market for cardiac amyloidosis is poised for significant expansion in the coming years, with projections indicating a rise to $8.71 billion by 2030, reflecting a compound annual growth rate of 8.7%. This anticipated growth trajectory is underpinned by several key drivers, including the advancing development of therapies aimed at modifying the disease’s course, a greater uptake of genetic testing for early identification, the proliferation of dedicated treatment centers for amyloidosis, increased investment in research concerning rare diseases, and a heightened emphasis on tailoring therapies to individual patients’ cardiac conditions. Looking ahead, prominent trends expected to shape this market include a stronger push for earlier and more precise diagnoses, the increasing utilization of sophisticated cardiac imaging technologies, a broader application of screening methods based on biomarkers, the development and implementation of more focused therapeutic strategies, and heightened awareness among cardiologists regarding this condition.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp
Cardiac Amyloidosis Market Growth Drivers: What Factors Are Accelerating Expansion?
The expanding segment of the elderly population is anticipated to be a significant driver for the expansion of the cardiac amyloidosis market in the future, as individuals aged 65 and older are more susceptible to age-related health conditions necessitating tailored medical care. This demographic surge is a consequence of factors such as extended lifespans, improvements in medical science, and decreased fertility rates, leading to a higher incidence of cardiac amyloidosis due to the age-related predisposition for amyloid protein deposition within the heart. Illustratively, the U.S., projected by the Population Reference Bureau in January 2024, will see its senior demographic (65+) escalate from 58 million in 2022 to 82 million by 2050, a substantial 47% rise, thereby fueling the cardiac amyloidosis market.
Cardiac Amyloidosis Market Segment Analysis And Revenue Opportunities
The cardiac amyloidosis market covered in this report is segmented –
1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis
2) By Treatment: Chemotherapy, Supportive Care, Stem Cell Transplant, Targeted Therapy
3) By End-User: Hospitals, Clinics
Subsegments:
1) By Light Chain Amyloidosis: AL (Immunoglobulin Light Chain) Amyloidosis with Cardiac Involvement, AL Amyloidosis without Cardiac Involvement
2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)
Cardiac Amyloidosis Market Trends: What Is Shaping Future Industry Growth?
A key strategic direction within the cardiac amyloidosis marketplace involves significant investment in novel technological advancements, particularly artificial intelligence (AI) driven software solutions designed for diagnostic purposes. These AI-powered, software-exclusive diagnostic instruments aim to refine the early identification of cardiac amyloidosis, thereby contributing to better patient prognoses in instances of this frequently overlooked condition. Such a device leverages AI algorithms to scrutinize echocardiographic imagery, pinpointing disease indicators without necessitating supplementary hardware or comprehensive patient data. A pertinent illustration of this trend occurred in November 2024, when Ultromics Ltd., a United Kingdom based innovator in health technology, achieved clearance from the U.S. Food and Drug Administration (FDA) for EchoGo Amyloidosis. This AI driven clinical instrument is specifically engineered for the prompt detection of cardiac amyloidosis and holds the distinction of being the inaugural device authorized for marketing under the FDA’s Total Product Lifecycle Advisory Program (TAP). Through its sophisticated AI capabilities, EchoGo Amyloidosis processes echocardiograms, enabling the identification of the disease from a solitary imaging clip, thus meeting the critical demand for earlier diagnosis before the condition advances undetected.
Cardiac Amyloidosis Market Leading Players Shaping Industry Direction
Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Neurimmune AG, Attralus Inc., Oncopeptides, SOM Biotech, Amylyx Pharmaceuticals, AstraZeneca plc, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb Company, AbbVie Inc., Roche Holding AG, Johnson & Johnson, CSL Limited
Access The Complete Cardiac Amyloidosis Market Report:
https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report
Cardiac Amyloidosis Market Geographic Distribution And Regional Opportunities
North Americawas the largest region in the cardiac amyloidosis market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
